Viking Therapeutics, Inc. (VKTX)
| Market Cap | 4.71B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -99.15M |
| Shares Out | 111.44M |
| EPS (ttm) | -0.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,544,332 |
| Open | 44.03 |
| Previous Close | 41.49 |
| Day's Range | 41.98 - 45.00 |
| 52-Week Range | 17.23 - 99.41 |
| Beta | 0.88 |
| Analysts | Strong Buy |
| Price Target | 106.75 (+152.66%) |
| Earnings Date | Feb 5, 2025 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phas... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is $106.75, which is an increase of 152.66% from the latest price.
News
Viking Therapeutics: Competition Fears Are Exaggerated
Viking Therapeutics' VK2735 reported promising results in February, with significant weight loss, however, shares have returned to prices before reporting VENTURE Phase II results. The company's pipel...
Viking Therapeutics: Holiday Gift
Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed i...
What's Going On With Viking Therapeutics Stock On Wednesday?
On Wednesday, Merck & Co Inc MRK and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small mole...
Viking Stock Pops, Then Drops On Latest Obesity / MASH Data - Why I'm Still Bullish
Viking Therapeutics is a strong contender in the GLP-1 obesity drug market - candidate VK2735 has the potential to challenge Eli Lilly's Zepbound and Novo Nordisk's Wegovy. The latest data from the or...
Viking Therapeutics Stock On Brink Of Death Cross As Weight Loss Hype Loses Momentum
Viking Therapeutics Inc. VKTX is nearing a pivotal moment as its stock hovers just above a potential death cross.
Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs
The Biden-Harris Administration has proposed expanding Medicare and Medicaid coverage for anti-obesity medications, aiming to address the high costs that have drawn criticism. In the U.S., Novo Nordis...
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
On Tuesday, Viking Therapeutics, Inc. VKTX highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred t...
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
The biotech's liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.
Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class Profile Highlighted by Robust...
RFK Jr.'s HHS nomination sparks concern over pharma stocks
President-elect Trump's decision to nominate Robert F. Kennedy Jr. as the Secretary of Health and Human Services (HHS) has sparked concerns, particularly about his skepticism toward the pharmaceutical...
RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.
The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr....
Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024
Results to be Featured in Oral Late Breaker Presentation SAN DIEGO , Nov. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focus...
Healthy Returns: Weight loss drug race heats up with pill data from Viking Therapeutics, AstraZeneca
AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here's how Americans voted on abortion access.
Viking Therapeutics soars then drops on obesity data
Jared Holz, Mizuho, joins 'Fast Money' to talk Viking Therapeutics and the biotech sector.
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results
Viking Therapeutics (VKTX) shares fell Monday, handing back early gains, as analysts questioned the path ahead for its developmental weight-loss drugs even after news of upbeat results in clinical tri...
Dow Jones, S&P 500 slip ahead of US elections; NVIDIA, Viking Therapeutics rise while Talen Energy declines
US stocks slumped on Monday as investors eagerly waited for the outcome of the US Presidential election on Tuesday. At the time of writing, the Dow Jones Industrial Average slid 175 points, or 0.4%, ...
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results...
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
TSLA Stalls on China Sales, CEG Sells Off, VKTX's Promising Weight Loss Drug Trial
After Tesla's (TSLA) earnings ripped the stock to the upside, lower-than-expected EV sales in China continued a notable downtrend since its report. Constellation Energy (CEG) sold off when its guidanc...
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics Inc VKTX announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations at ObesityWeek 2024.
Should you buy Viking Therapeutics (VKTX) after today's spike?
Viking Therapeutics (NASDAQ: VKTX) saw its stock surge over 10% in pre-market trading on November 4, following the release of highly encouraging early-stage results for its experimental obesity drug, ...
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations.
Viking Therapeutics Reports New Data from VK2735 Obesity Program at ObesityWeek® 2024
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Rel...
Viking Therapeutics stock jumps after ‘great' trial of weight-loss drug
Viking Therapeutics stock rose in early trade on Monday as the company showed its oral weight-loss drug in clinical trials was successful.
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...